Micardis: Effective Blood Pressure Control for Cardiovascular Health
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.74 | $52.21 (0%) | 🛒 Add to cart |
| 60 | $1.34 | $104.42 $80.33 (23%) | 🛒 Add to cart |
| 90 | $1.19 | $156.63 $107.43 (31%) | 🛒 Add to cart |
| 120 | $1.12 | $208.85 $134.54 (36%) | 🛒 Add to cart |
| 180 | $1.05 | $313.27 $189.77 (39%) | 🛒 Add to cart |
| 270 | $1.02 | $469.90 $274.11 (42%) | 🛒 Add to cart |
| 360 | $0.99
Best per pill | $626.54 $357.45 (43%) | 🛒 Add to cart |
| Product dosage: 40mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.48 | $74.30 (0%) | 🛒 Add to cart |
| 60 | $1.96 | $148.60 $117.48 (21%) | 🛒 Add to cart |
| 90 | $1.80 | $222.90 $161.65 (27%) | 🛒 Add to cart |
| 120 | $1.70 | $297.20 $203.82 (31%) | 🛒 Add to cart |
| 180 | $1.62 | $445.80 $291.18 (35%) | 🛒 Add to cart |
| 270 | $1.56 | $668.71 $420.70 (37%) | 🛒 Add to cart |
| 360 | $1.53
Best per pill | $891.61 $550.23 (38%) | 🛒 Add to cart |
Synonyms | |||
Micardis (telmisartan) is an angiotensin II receptor blocker (ARB) prescribed for the management of hypertension in adults. It works by blocking the action of certain natural substances that tighten blood vessels, allowing blood to flow more smoothly and the heart to pump more efficiently. This medication is also indicated to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors. Clinical studies have demonstrated its efficacy in providing 24-hour blood pressure control with a single daily dose. As a well-tolerated treatment option, Micardis plays a significant role in long-term cardiovascular risk management strategies under appropriate medical supervision.
Features
- Active ingredient: Telmisartan
- Available in tablet strengths: 20 mg, 40 mg, and 80 mg
- Once-daily dosing regimen
- Angiotensin II receptor blocker (ARB) class medication
- 24-hour blood pressure control
- Available as film-coated tablets
- Not a controlled substance
- Prescription-only medication
Benefits
- Effectively lowers high blood pressure to reduce strain on the heart and blood vessels
- Provides consistent 24-hour blood pressure control with single daily dosing
- Reduces the risk of stroke, heart attack, and cardiovascular mortality in high-risk patients
- Generally well-tolerated with a favorable side effect profile compared to other antihypertensives
- Does not require dosage adjustment in patients with renal impairment
- May be used as monotherapy or in combination with other antihypertensive agents
Common use
Micardis is primarily indicated for the treatment of essential hypertension in adults. It is also used for cardiovascular risk reduction in patients 55 years of age or older who are at high risk for developing major cardiovascular events and are unable to take ACE inhibitors. The medication may be used as monotherapy or in combination with other antihypertensive agents, particularly thiazide diuretics such as hydrochlorothiazide. Healthcare providers may prescribe Micardis for patients who have experienced cough with ACE inhibitor therapy, as ARBs generally do not cause this side effect. The medication is typically part of a comprehensive treatment plan that includes lifestyle modifications such as dietary changes, exercise, and weight management.
Dosage and direction
The recommended initial dose of Micardis is 40 mg once daily. Depending on blood pressure response, the dosage may be increased to 80 mg once daily. Some patients may benefit from starting at 20 mg daily, particularly those with hepatic impairment or volume depletion. Micardis may be administered with or without food. The tablets should be swallowed whole with a glass of water. For patients requiring additional blood pressure control, Micardis may be combined with other antihypertensive agents, particularly thiazide diuretics. Dosage adjustment is recommended in patients with severe renal impairment or hepatic impairment. Blood pressure response should be monitored periodically, and dosage adjustments made at intervals of at least 2 weeks to allow full therapeutic effect.
Precautions
Patients should be monitored for hypotension, particularly after initiation or dosage increase, especially in volume-depleted patients or those on diuretic therapy. Renal function should be assessed prior to treatment and periodically thereafter, as drugs that affect the renin-angiotensin system may cause changes in renal function. Use with caution in patients with renal artery stenosis, as deterioration in renal function may occur. Monitor serum potassium levels, particularly in patients with renal impairment, diabetes, or those taking potassium supplements or potassium-sparing diuretics. Exercise caution in patients with hepatic impairment, as telmisartan is extensively metabolized in the liver. Not recommended during pregnancy due to potential fetal harm. Use with caution in elderly patients who may have age-related renal function decline.
Contraindications
Micardis is contraindicated in patients with known hypersensitivity to telmisartan or any component of the formulation. Concomitant use with aliskiren is contraindicated in patients with diabetes. Do not co-administer with ACE inhibitors in patients with diabetic nephropathy. Contraindicated during the second and third trimesters of pregnancy due to risk of fetal injury and death. Avoid use in patients with severe hepatic impairment (Child-Pugh class C). Not recommended for use in patients with biliary obstructive disorders. Contraindicated in patients with severe renal impairment (CrCl <15 mL/min) not on dialysis. Do not use in patients with hypotension or hemodynamically significant obstructive cardiac disease.
Possible side effect
Common side effects may include dizziness (1-3%), upper respiratory tract infection (1-7%), back pain (0-3%), sinusitis (0-3%), diarrhea (1-4%), and fatigue (1-2%). Less frequently reported side effects include headache, indigestion, myalgia, cough, and peripheral edema. Serious but rare side effects may include angioedema, renal impairment, hyperkalemia, hypotension, and elevated liver enzymes. Allergic reactions including rash, pruritus, and urticaria may occur. Some patients may experience orthostatic hypotension, particularly when initiating therapy. Laboratory abnormalities may include increased serum creatinine, blood urea nitrogen, and potassium levels. Report any persistent or severe side effects to healthcare provider immediately.
Drug interaction
Micardis may interact with other medications that affect blood pressure, including diuretics, other antihypertensives, and beta-blockers, potentially increasing the risk of hypotension. Concurrent use with potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to hyperkalemia. NSAIDs may reduce the antihypertensive effect and increase risk of renal impairment. Lithium levels may increase when co-administered with Micardis. Use with digoxin may increase digoxin concentrations. Ramipril and other ACE inhibitors may increase the risk of renal impairment and hyperkalemia. Alcohol, barbiturates, or narcotics may potentiate the hypotensive effect. Always inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.
Missed dose
If a dose of Micardis is missed, take it as soon as remembered on the same day. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed dose. Maintaining a consistent dosing schedule is important for optimal blood pressure control. Consider using reminder tools such as pill organizers or alarm settings to help maintain regular dosing. If multiple doses are missed, contact your healthcare provider for guidance, as blood pressure may not be adequately controlled. Do not make any dosage adjustments without consulting your healthcare provider.
Overdose
In case of suspected overdose, symptoms may include severe hypotension, tachycardia, bradycardia, dizziness, and decreased renal function. Laboratory findings may include electrolyte imbalances, particularly hyperkalemia. If overdose occurs, provide supportive treatment including gastric lavage if ingestion was recent and activated charcoal if appropriate. Correct electrolyte imbalances and monitor renal function. Hypotension should be treated with intravenous normal saline solution. Vasopressors may be required in cases of severe hypotension. Hemodialysis is not effective for removing telmisartan from the bloodstream due to high protein binding. Seek immediate medical attention or contact a poison control center. Provide healthcare professionals with information about the amount ingested and time of ingestion.
Storage
Store Micardis tablets at room temperature between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not store in bathrooms or other areas with high humidity. Keep out of reach of children and pets. Do not use tablets that are discolored, damaged, or beyond the expiration date printed on the packaging. Proper storage ensures medication stability and effectiveness. Do not transfer tablets to other containers unless using a properly labeled pill organizer. Avoid freezing the medication. Dispose of unused medication properly according to local regulations or through medication take-back programs.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting, changing, or stopping any medication. The information provided may not cover all possible uses, directions, precautions, or interactions. Individual patient responses to medication may vary. Healthcare providers should use their professional judgment when prescribing Micardis based on individual patient characteristics and needs. This information is not a substitute for professional medical care and should not be used for diagnosing or treating health problems. In case of emergency, seek immediate medical attention.
Reviews
Clinical studies have demonstrated Micardis’ efficacy in blood pressure control with once-daily dosing. The ONTARGET trial showed telmisartan was non-inferior to ramipril in reducing cardiovascular events with better tolerability. Many patients report satisfactory blood pressure control with minimal side effects. Healthcare providers appreciate its 24-hour coverage and favorable metabolic profile. Some studies indicate potential benefits beyond blood pressure control, including possible effects on glucose metabolism. Patient satisfaction surveys indicate good tolerability with lower incidence of cough compared to ACE inhibitors. Long-term follow-up studies support its safety profile for chronic hypertension management. Real-world evidence confirms the clinical trial findings regarding efficacy and tolerability in diverse patient populations.